🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Is there a role for ADC in EGFR+ metastatic NSCLC? HERTHENA-Lung01 patritumab deruxtecan data are promising, although many questions remain. Read our view Jordi Remon in the accompanying editorial, finally out Journal of Clinical Oncology ascopubs.org/doi/abs/10.120… #LCSM

What a great time to study Ret+ tumors Practice changing data for #NSCLC and MTC presented at #ESMO23 presidential symposium Selpercatinib > cabozantinib or vandetanib in Ret+ medullary thyroid carcinoma Selpercatinib > chemo-io in 1st line for Ret+ NSCLC RETpositive

Incredibily amazing discussion conducted by @BenjaminBesseMDtk conclude this exciting plenary session on #NSCLC with rare alterations -> The (un)necessary trials So proud of being part of his motivated team!

🔹 Gustave Roussy à l'#ESMO2023 🔹 Découvrez les posters des experts de l'institut à ESMO - Eur. Oncology 👇 🔸 Dr Isabelle Borget 🔸 Dr Kristi Beshiri 🔸 Dr Arianna Marinello, MD

We’ll start 2024 with this ttx algorithm for NSCLC🫁including non-metastatic NSCLC Pending Qx💡: ✏️Will ADC overcome docetaxel? 📛 ✏️ADC 2n L for oncogenic-driven? 🎉 ✏️Perioperative vs Induction?🥊 ✏️Adjuvant RET TKI?🧬 ✏️Academic trials for ↗️ / ↘️ ttx And more!! @oncoalert

ESMO Guideline: Oncogene-Addicted #mNSCLC. Developed due 2 advances in biomarker identificatn & targeted therapies; updated recommendatns & tx algorithms on new & clinically relevant biomarker identificatn, targeting & adv disease managemt.ow.ly/b89e50QkVFs Annals of Oncology

Ceralasertib (ATR kinase inhibitor) for 7 days + durvalumab q4w: a promising combo post chemo-IO in pts with advanced NSCLC! nature.com/articles/s4159…. Benefit seen in all comers, including ATM altered NSCLC & manageable safety. Currently tested vs docetaxel in the trial Latify.

We know how will be the next Research Building Gustave Roussy (Q1 2027) 32 000 m2 , 60 research teams in 15 Centers, 15 core facilities, 1400 staff. Each floor will include 10 teams of biology that will surround Data Science / Epidemiology teams. We are welcoming new teams !

Great work on blood based NGS in head and neck carcinoma presented at AACR Annual Meeting by Filippo Dall'Olio from Gustave Roussy Board #10 section #40

Interesting work presented by Mihaela Aldea at AACR Annual Meeting 2024 ✨✨✨ Gustave Roussy and Lifen collaborate help data collection and facilitate clinical research Come and have a look at her poster in section #36 board #29 #AACR

One-minute applause and standing ovation for the PFS LAURA in today plenary session at #ASCO24 🏆 Consolidation therapy with osimertinib in unresectable stage III NSCLC improves PFS with an outstanding HR of 0.16 What a great time to cure lung cancer patients!

The time for a practice-changing trial in locally advanced SCLC has come! 🏆 In the ADRIATIC trial: significant OS benefit with durvalumab consolidation versus placebo after CTRT: - 55.9 versus 33.4 months OS at the first interim analysis #ASCO24

From the largest RET-registry, a huge multicentric effort, Arianna Marinello, MD presents outcomes to inhibitors/chemo in RET+ advanced NSCLC according to histological subtypes. Gustave Roussy ESMO - Eur. Oncology

🔹Gustave Roussy à l'#ESMO24 Les experts de l'institut sont présents pour leurs sessions poster. 💪 Mora Guardanamie, Arianna Marinello et Mihaela Aldea, Adrien Rousseau et Filippo Dall’Olio. ⤵

🏆 Un grand bravo à Dr Antonio di Meglio, Dr Cédric Pobel, Dr Adèle Bonato, Dr Adrien Rousseau, Dr Arianna Marinello pour le prix du "Merit Travel Grant" de l'#ESMO24.

What happens in the tumor and in the host when tumor burden increases? Could we use tMTV to decide when intensify the treatment in aNSCLC? We tried to answer these questions in our multicentric effort Benjamin Besse Gustave Roussy

The use of liquid biopsy can allow a better selection of NSCLC patients candidate to IO or Chemo-IO. Very interesting data, further confirming the prognostic role of Tumor Fraction at baseline International Society of Liquid Biopsy Christian Rolfo Congrats Filippo Dall'Olio and team!

So grateful for the great opportunity to participate to IASLC Academy this year!

Proud of being part of these amazing research group in Gustave Roussy, made of great professionals and mentors

Excited to share our article out in JAMA Oncology The first to report the expression of membrane targets in RET+ NSCLC in a wide international cohort Have a look: jamanetwork.com/journals/jamao… Gustave Roussy Caris Life Services